# iinnovate-1 (NCT03215030)

> A Study of Modakafusp Alfa on Adult Participants With Relapsed/Refractory Multiple Myeloma

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03215030
- Phase: PHASE1, PHASE2
- Status: TERMINATED
- Sponsor: Teva Branded Pharmaceutical Products R&D LLC
- Conditions: Multiple Myeloma
- Interventions: Modakafusp alfa; Dexamethasone
- Enrollment: 272
- Primary outcome: Part 1: Percentage of Participants Reporting One or More Treatment Emergent Adverse Events (TEAEs)
- Primary outcome: Part 1: Number of Participants With Dose-limiting Toxicities (DLTs)
- Primary outcome: Part 1: Percentage of Participants Reporting One or More Grade 3 or Higher TEAEs
- Primary outcome: Part 1: Percentage of Participants Reporting One or More Serious Treatment-emergent Adverse Events (Serious TEAEs)
- Primary outcome: Part 1: Percentage of Participants Who Discontinued the Treatment Because of TEAE
- Primary outcome: Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Delay
- Primary outcome: Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Interruptions
- Primary outcome: Part 1: Percentage of Participants With TEAEs Resulting in Dose Modifications: Dose Reductions
- Primary outcome: Part 1: Percentage of Participants With Clinically Significant Laboratory Values
- Primary outcome: Part 1: Percentage of Participants With Clinically Significant Vital Signs Measurements
- Primary outcome: Part 2: Overall Response Rate (ORR)
- Primary outcome: Part 3: Overall Response Rate (ORR) Assessed by Independent Review Committee (IRC)

## Indexed commentary on iinnovate-1 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- YouTube: 1
- X threads: 1
- Bluesky threads: 1

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=iinnovate-1-nct03215030